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Abstract
Background. The aim of the study was to investigate if and how, in diabetes mellitus (DM) patients, serum
Magnesium (Mg) concentration influences serum lipids. A cross-sectional study was conducted on diabetic
mellitus (DM) patients with various kidney functions, not yet on dialysis.
Material and methods. Serum lipoprotein (a), glycosylated haemoglobin (HbA1c), serum magnesium (Mg),
serum creatinine (creat) and serum lipids, consisting of triglycerides (Tg), cholesterol (Chol) and high density
lipoprotein (HDL) were measured.
Results. Study patients included 122 patients (82 F, 40 M). The mean patient's age was 63 (± 10) years.
The mean length of time they were diabetic was 7.4 (± 5.8) years (median: 6 years). The mean serum Mg
was 2 (± 0.4) mg/dl (median: 1.99 mg/dl). The mean creatinine clearance was 64 (± 24) cc/min (median:
64 cc/min). In this study significant inverse correlations of serum Mg with serum cholesterol and LDL, and also
non significant correlations of serum Mg with serum Lp (a), HDL, Tg and with serum HbA1c were seen.
Moreover, a significant inverse correlation of serum Mg with the patients' ages and a significant positive
correlation of serum Mg with serum creatinine were also seen.
Conclusions. It seems that in diabetic patients, kidney function is a key role in the regulation of serum Lp(a)
levels instead of other factors like serum Mg level. Our findings further support the importance of Mg supple-
mentation in diabetes mellitus patients. In our study no significant correlation between serum Mg with serum
HDL and Tg were found, which needs further investigation.
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Introduction
In recent years, the biological role and properties of
metal ions have begun to be reconsidered due to gre-
ater importance of inorganic bioions in the explanation
of numerous biologic processes. Magnesium (Mg) is an
important intracellular cation that is distributed into three
major compartments: mineral phase of bones (65%),
intracellular space (34%) and extracellular fluid (1%)
[1]. About one-third of the circulating magnesium is
bound to plasma proteins, with the remaining two-thirds
free and presumably biologically available [1, 2]. In se-
veral studies reduced magnesium concentrations have
been observed in diabetic adults [3–7] and children [8,
9] despite good nutritional status [10], which probably
results from glycosuria-related hypermagnesiuria, nutri-
tional factors or hyperinsulinaemia [3]. A large body of
evidence that shows a link between hypomagnesemia
and reduction of tyrosine-kinase activity at the insulin
receptor level, which may result in the impairment of
insulin action and development of insulin resistance, has
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been progressively accumulated in previous years [11–
–16]. Various evidence suggests that magnesium sup-
plementation could be useful in the treatment of diabe-
tes and to prevent the development of its chronic com-
plications [17–19], and experimental studies have also
shown that hypomagnesemia inhibits prostacyclin recep-
tor function [20], producing an imbalance between pro-
stacyclin and thromboxane effects [21]. Hypomagnese-
mia can increase platelet reactivity, increase vascular and
adrenal responses to angiotensin II, enhance thrombo-
xane A2 (TXA2) release, and lead to organ damage from
free radicals [22–25]. Magnesium deficiency also has
a role in the perturbation of lipid metabolism in the non-
-uremic population, especially in diabetic patients [26].
Previously, we and others have shown that there is a cor-
relation between dyslipidemia and serum magnesium l in
end-stage renal failure patients undergoing haemodialy-
sis treatment [27, 28]. In light of the evidence of magne-
sium imbalance in diabetes mellitus, it is important to study
the association of serum magnesium with lipids. Indeed,
controversial reports are available regarding the effect of
magnesium (Mg) on lipid profile and glycaemic control in
diabetic patients. A number of studies have reported
beneficial effects of magnesium supplementation on pla-
sma cholesterol and LDL cholesterol, and an increase of
HDL cholesterol level [26, 29, 30]. This study was desi-
gned to investigate if and how in diabetes mellitus (DM)
patients, the serum magnesium (Mg) concentration influ-
ence serum lipids. We designed this study on a group of
diabetes mellitus patients who had various kidney func-
tions, and were not yet on dialysis.
Material and methods
Patients
This cross-sectional study was conducted on diabe-
tic mellitus patients under treatment of either an oral
hypoglycaemic agent with /- biguanides or insulin NPH
with/- Insulin crystal injections with various dosages who
were admitted to the hospital to control their diabetes.
These patients were recruited between January and
September of 2005. Among the study patients, ones who
had hypertension took antihypertensive drugs consisting
of calcium channel blocker (amlodine or diltiazem), an-
giotensin-converting enzyme inhibitors (ACE) or angio-
tensin receptor antagonists (ARA) in various doses. Exc-
lusion criteria included taking diuretics, the presence of
other chronic or acute infections and the use of lipid-
lowering medications. The study was carried out in Hajar
Medical educational and Therapeutic Centre of Shahre-
kord University of Medical Sciences of Iran. All patients
signed the consent form for participation in this study.
After admission all patients' medical histories were
examined concerning the length of the time they were
diabetic and their medicament for DM and HTN. Pa-
tients were also examined for blood pressure (BP), body
mass index, heart and lower extremities pulse and their
feet were examined for ulcers.
Laboratory methods
Blood samples were collected after an overnight fast.
The blood samples were centrifuged within 15 min of
venopuncture, and serum lipoprotein(a) [Lp(a)] measu-
rements were determined by means of a commercial
enzyme-linked immunosorbent assay kit [Macra® Lp(a)
manufactured by Strategic Diagnostics Inc. for Trinity
Biotech USA, Jamestown, NY, USA].
The patients' glycosilated hemoglobine (HbA1c) was
also measured by chromatography using Hb-Gold of UK,
the normal value in our laboratory is (less than or equal
to) 6.1%. Levels of serum magnesium (Mg), albumin
(Alb), serum creatinine (creat), blood urea nitrogen
(BUN) and total protein were measured using standard
methods. Other lipids consisting of triglycerides (Tg),
cholesterol (Chol) and high density lipoprotein (HDL)
were also measured using standard methods. Body mass
index (BMI) was calculated using the standard formula
(weight in kilograms/height in metres squared: kg/m2).
Serum LDL-C was calculated by Friedewald's formula
[31]. Creatinine clearance (CrCL) was evaluated from
serum creatinine, age and body weight [32].
Statistical analysis
Results are expressed as the mean ± SD and me-
dian values. Statistical correlations were assessed using
a partial correlation test. Comparison between female
and male gender data was assessed using Students'
t-test. All analyses were performed with the SPSS stati-
stical package (version 11.500 for Windows; SPSS, Chi-
cago, USA). Statistical significance was determined at
a p-value < 0.05.
Results
The present study included 122 patients (82 F, 40
M). Baseline characteristics of the patients are descri-
bed in Table I .The mean patient's age was 63 (± 10)
years. The mean length of time they were diabetic was
7.4 (± 5.8) years (median: 6 years). The mean serum
Mg was 2 (± 0.4) mg/dl (median: 1.99 mg/dl). The mean
creatinine clearance was 64 (± 24) cc/min (median:
64 cc/min). Serum Lp (a) levels > 30 mg/dl was found
in 29 patients (23.8%). Mean ± SD of serum Chol and
LDL of the patients were 198 ± 52 and 112 ± 37 res-
pectively.
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Table I. Minimum, maximum, mean ± SD and median values of patients' data and laboratory tests of the patients
Patients (n = 122) Minimum Maximum Mean ± SD Median
Age [years] 25 84 63 ± 11 64
Duration of DM [years] 0.1 25 7.4 ± 6.8 6
Duration of HTN [years] 0.00 25 3.2 ± 4.5 0.80
BMI [kg/m2] 19.9 53 25.5 ± 4.5 25.3
Creatinine clearance [cc/min] 10 110 64 ± 24 64
Lp(a) [mg/dl] 0.10 134 22.2 ± 24.8 18.3
Alb [g/dl] 2.5 7.5 4.9 ± 1 4.9
Total protein [g/dl] 5 12.5 7.2 ± 0.9 7
HbA1c (%) 3.9 13.3 7.6 ± 1.9 7.6
Cholesterol [mg/dl] 90 388 198 ± 52 192
Triglycerides [mg/dl] 37 580 183 ± 102 155
LDL [mg/dl] 44 210 112 ± 37 112
HDL [mg/dl] 19 128 47 ± 18 44
Magnesium [mg/dl] 1 3.29 2 ± 0.4 1.99
Creatinine [mg/dl] 0.6 10 1.32 ± 1.34 1
DM — diabetes mellitus; HTN — hypertension; BMI — body mass index; LDL — low density lipoprotein, HDL — high density lipoprotein; Lp(a) — lipoprotein A;
Alb — albumin; SD — standard deviation
In this study no significant difference of duration of
DM, age of the patients, CrCL, BMI, HbA1c and serum
Mg, serum Alb, Lp(a), LDL, HDL and total protein be-
tween males and females was found (P.N.S). A signifi-
cant difference of serum cholesterol (p < 0.001) and
triglyceride (p = 0.001) between males and females was
found (Figure 1). In this study significant inverse corre-
lations of serum Mg with cholesterol (r = –0.20,
p = 0.023) (Figure 2) and also with serum LDL (r = –0.20,
p = 0.024) (Figure 3) were found (adjusted for age, du-
ration of DM and creatinine clearance). No significant
correlation between serum Mg with serum Lp (a), HDL,
Alb and serum Tg or with serum HbA1c were seen
(P.N.S). Moreover, a significant inverse correlation of
serum Mg with ages of the patients (r = –0.18, p = 0.045)
(Figure 4) (adjusted for duration of DM and creatinine
clearance) was seen. Furthermore, a significant positive
correlation of serum Mg with serum creatinine (r = 0.19,
p = 0.036) (adjusted for age, duration of DM and total
protein) was seen too. Also, a weak negative correla-
Figure 1. Significant difference of serum cholesterol and
triglyceride between males and females
Figure 2. Significant inverse correlation of serum Mg
with serum cholesterol
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tion between serum Mg and duration of DM (r = –0.18,
p = 0.055) (adjusted for age, duration of HTN, BMI,
HbA1c level and Chol, LDL, Tg and also serum creat
was found too).
Discussion
The principle findings of the present study were si-
gnificant inverse correlations of serum Mg with serum
cholesterol and LDL, and also non significant correla-
tions of serum Mg with serum Lp(a), HDL, Tg and with
serum HgbA1c. Moreover, a significant inverse correla-
tion of serum Mg with ages of the patients and a signifi-
cant positive correlation of serum Mg with serum cre-
atinine were seen as well. Magnesium is known to play
an important role in carbohydrate metabolism, and its
imbalance has been implicated in diabetes mellitus both
as a cause and a consequence [33–36]. Hypomagnese-
mia has been observed in both animal [35–37] and hu-
man subjects with type 1 and type 2 diabetes mellitus
[37–41].The etiology of hypomagnesemia in diabetes
cannot be clearly explained and serum magnesium le-
vels have been shown to be inversely related to the se-
verity of diabetes [42]. Magnesium deficiency in humans
is unlikely to occur from a simple lack of foods conta-
ining this mineral, except in advanced forms of malnu-
trition [8]. According to the consensus of a panel on
magnesium metabolism in diabetes mellitus [43], diabe-
tic patients have additional risk factors for hypomagne-
semia and magnesium status, Magnesium may also play
a role in the release of insulin, and magnesium depletion
has an atherogenic potential [44–46]. The mechanisms
of long-term complications of diabetes are not clearly
explained, and hypomagnesemia may be a contributing
factor to these complications, particularly ischemic he-
art disease [14, 47], retinopathy [4, 48] and bone loss
[49, 50]. In a study conducted by Lal et al. on 40 pa-
tients of type 2 diabetes mellitus (DM) and 54 age and
sex matched non-diabetic controls, the diabetic patients
(study group) were supplemented with 600 mg of Mg
oxide daily for 12 weeks. They were followed up every
four weeks (for a total duration of twelve weeks) and
investigated for the above parameters. Mean serum ma-
gnesium at baseline in the diabetic patients was signifi-
cantly lower than that in controls (1.44 ± 0.48 mg/dl vs.
2.29 ± 0.33 mg/dl). A significant fall in serum total cho-
lesterol, LDL cholesterol and triglycerides and a rise in
HDL cholesterol levels was observed 48 weeks after
initiation of magnesium supplementation and continued
till the end of the study i.e. 12 weeks. They concluded
that Mg supplementation resulted in a beneficial effect
on the lipid profile of these patients [30]. The useful-
ness of chronic magnesium supplementation in redu-
cing plasma cholesterol and LDL cholesterol, and in in-
creasing HDL cholesterol was also shown by Corica et
al. [29] and Baydas et al. [51].The subject of study of
previous investigators was mainly the effect of Mg sup-
plementation on lipid profiles of diabetic patients. To
our best knowledge this is the first report investigating
the association of serum Lp(a) with serum magnesium
in diabetic patients with various kidney functions not yet
on dialysis. The mean creatinine clearance of our study
patients were 64 ± 24 cc/min (median: 64 cc/min).
In our study we adjusted the results according to the
kidney function of the patients, although, by decreasing
the renal function, dyslipidemia might also supervene
the effects of serum Mg or poorly controlled diabetes.
Figure 3. Significant inverse correlation of serum Mg
with serum LDL
Figure 4. Significant inverse correlation of serum Mg
with  the patients age
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While we previously showed the positive association
of serum Lp(a) with serum Mg in haemodialysis pa-
tients [28], in this study even after adjusting for multi-
ple confounding factors, no significant association be-
tween serum Mg and serum Lp(a) was seen. Taking >
30 mg/dl as the cut off value for Lp(a), we had serum
Lp (a) levels > 30 mg/dl in 29 patients (23.8%). It se-
ems that kidney function is a key role in the regulation
of serum Lp(a) levels instead of other factors [52, 53]
in diabetic patients. We also showed inverse correla-
tions of serum Mg with serum cholesterol and LDL
levels, a finding which further supports the importan-
ce of Mg supplementation in diabetes mellitus patients.
In our study no significant correlation between serum
Mg with serum HDL and Tg were found, which needs
further investigation. Recent studies in rats have shown
that magnesium deficiency produces hypertriglycere-
mia, hypercholesterolemia, increased low-density lipo-
proteins (LDL), and reduced high-density lipoprotein
(HDL) through reduced triglyceride clearance, dimini-
shed activity of lecithin cholesterol acetyltransferase
(LCAT) and lipoprotein lipase, and increased activity
of HMG-COA reductase [54]. The association betwe-
en hypomagnesemia and hypertriglyceremia has been
confirmed in studies of pigs [54]. However, the asso-
ciation between lipid abnormalities and hypomagne-
semia has not been fully understood in human studies.
Our results emphasize the importance of serum Mag-
nesium level and the clinical impact of these findings
merit further investigation.
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